Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3931 AL 3945

Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives

de Castro AA, da Cunha EFF, Pereira AF, Soares FV, Leal DHS, Kuca K, Ramalho TC.

Curr Alzheimer Res. 2018;15(12):1161-1178. doi: 10.2174/1567205015666180813150703.

Effect and Safety of Huannao Yicong Formula () in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Double-Blinded, Donepezil-Controlled Trial

Yang Y, Liu JP, Fang JY, Wang HC, Wei Y, Cao Y, Liu JG, Liu LT, Li H.

Chin J Integr Med. 2019 Aug;25(8):574-581. doi: 10.1007/s11655-018-3054-7. Epub 2018 Aug 14.

Stem Cells as Potential Targets of Polyphenols in Multiple Sclerosis and Alzheimer's Disease

Tandon A, Singh SJ, Chaturvedi RK.

Biomed Res Int. 2018 Jul 12;2018:1483791. doi: 10.1155/2018/1483791. eCollection 2018.

Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study

Salloway S, Marshall GA, Lu M, Brashear HR.

Curr Alzheimer Res. 2018;15(13):1231-1243. doi: 10.2174/1567205015666180821114813.

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study

Timmers M, Streffer JR, Russu A, Tominaga Y, Shimizu H, Shiraishi A, Tatikola K, Smekens P, Börjesson-Hanson A, Andreasen N, Matias-Guiu J, Baquero M, Boada M, Tesseur I, Tritsmans L, Van Nueten L, Engelborghs S.

Alzheimers Res Ther. 2018 Aug 23;10(1):85. doi: 10.1186/s13195-018-0415-6.

Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis

Liu D, Cao B, Zhao Y, Huang H, McIntyre RS, Rosenblat JD, Zhou H.

Neurosci Lett. 2018 Nov 1;686:10-16. doi: 10.1016/j.neulet.2018.08.038. Epub 2018 Aug 29.

Resveratrol's Potential in the Adjunctive Management of Cardiovascular Disease, Obesity, Diabetes, Alzheimer Disease, and Cancer

Kulashekar M, Stom SM, Peuler JD.

J Am Osteopath Assoc. 2018 Sep 1;118(9):596-605. doi: 10.7556/jaoa.2018.133.

Neuroprotective Activity of Sitagliptin via Reduction of Neuroinflammation beyond the Incretin Effect: Focus on Alzheimer's Disease

Wiciński M, Wódkiewicz E, Słupski M, Walczak M, Socha M, Malinowski B, Pawlak-Osińska K.

Biomed Res Int. 2018 Aug 16;2018:6091014. doi: 10.1155/2018/6091014. eCollection 2018.

Alzheimer's Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment

Dos Santos Picanco LC, Ozela PF, de Fatima de Brito Brito M, Pinheiro AA, Padilha EC, Braga FS, de Paula da Silva CHT, Dos Santos CBR, Rosa JMC, da Silva Hage-Melim LI.

Curr Med Chem. 2018;25(26):3141-3159. doi: 10.2174/0929867323666161213101126.

A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer's Disease

O'Bryant SE, Zhang F, Johnson LA, Hall J, Edwards M, Grammas P, Oh E, Lyketsos CG, Rissman RA.

J Alzheimers Dis. 2018;66(1):97-104. doi: 10.3233/JAD-180619.

Heat Shock Proteins in Alzheimer's Disease: Role and Targeting

Campanella C, Pace A, Caruso Bavisotto C, Marzullo P, Marino Gammazza A, Buscemi S, Palumbo Piccionello A.

Int J Mol Sci. 2018 Sep 1;19(9):2603. doi: 10.3390/ijms19092603.

Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities

Fu WY, Wang X, Ip NY.

ACS Chem Neurosci. 2019 Feb 20;10(2):872-879. doi: 10.1021/acschemneuro.8b00402. Epub 2018 Sep 17.

The efficacy and safety of memantine for the treatment of Alzheimer's disease

Matsunaga S, Kishi T, Nomura I, Sakuma K, Okuya M, Ikuta T, Iwata N.

Expert Opin Drug Saf. 2018 Oct;17(10):1053-1061. doi: 10.1080/14740338.2018.1524870. Epub 2018 Sep 26.

Rollercoaster ride of kynurenines: steering the wheel towards neuroprotection in Alzheimer's disease

Sharma R, Razdan K, Bansal Y, Kuhad A.

Expert Opin Ther Targets. 2018 Oct;22(10):849-867. doi: 10.1080/14728222.2018.1524877. Epub 2018 Sep 25.

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease

Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Lüönd RM, Machauer R, Veenstra SJ, Hurth K, Rueeger H, Tintelnot-Blomley M, Staufenbiel M, Shimshek DR, Perrot L, Frieauff W, Dubost V, Schiller H, Vogg B, Beltz K, Avrameas A, Kretz S, Pezous N, Rondeau JM, Beckmann N, Hartmann A, Vormfelde S, David OJ, Galli B, Ramos R, Graf A, Lopez Lopez C.

EMBO Mol Med. 2018 Nov;10(11):e9316. doi: 10.15252/emmm.201809316.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias